72795-01-8

Usage

Uses

Used in Pharmaceutical Research:
(±)-erythro-(S,S)-1-[2,3-(Dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanolhydrochloride is used as a research tool for blocking β-adrenergic signaling in various experiments. This helps scientists understand the role of β2 receptors in different physiological processes and the potential therapeutic effects of modulating these receptors.
Used in Enzyme Inhibition Studies:
(±)-erythro-(S,S)-1-[2,3-(Dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanolhydrochloride is also used to counteract the degradation by endogenous T-lymphocyte monoamine oxidases, which are enzymes involved in the breakdown of neurotransmitters and other amines. By inhibiting these enzymes, researchers can study the effects of increased levels of neurotransmitters and other amines on cellular function and signaling pathways.
Used in Determining Receptor Subtypes:
(±)-erythro-(S,S)-1-[2,3-(Dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanolhydrochloride aids in determining the specific receptor subtype necessary for isoproterenol to induce up-regulation of gene transcripts. This information is crucial for understanding the molecular mechanisms underlying the actions of adrenergic agonists and for developing more targeted therapeutic agents.
Used in Enantioselective Studies:
The (R,R)-enantiomer of ICI 118,551 serves as a highly selective β2-adrenoceptor antagonist, while the (S,S)-enantiomer is the most potent. These enantiomers are used in enantioselective studies to investigate the differences in biological activity and receptor binding preferences between the two mirror-image forms of the compound. This can provide valuable insights into the structure-activity relationships of β2-adrenergic receptor antagonists and guide the design of more effective and selective drugs.

Biochem/physiol Actions

ICI 118,551 has been used to treat vasomotor migraines and somatic troubles related to anxiety state.